AGN-214868
Phase 2Small molecule
AbbVieAGN-214868 is one of 60 small molecule programs targeting Urinary incontinence. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
69 competitors in Postherpetic Neuralgia
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Ketalar
AAultman Health Foundation
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Neurontin
VViatris Specialty LLC
Phase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lidoderm
Endo PharmaceuticalsApproved
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Dolophine
HHikma Pharmaceuticals LLC
Phase 3
Norpramin
VValidus Pharmaceuticals
Phase 3
Pamelor
SSpecgx
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Postherpetic Neuralgia2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AGN-214868. EMBL-EBI & Wellcome Sanger Institute.
- [4]